Image Source: Pixabay

NeuroPace (NPCE - Free Report) is a $200 million commercial-stage medical device company focused on developing products to treat and transform the lives of patients suffering from epilepsy. NeuroPace Inc. is based in Mountain View, CA.

The company's patented RNS® System is the only FDA-approved epilepsy device that delivers personalized treatment by responding to abnormal brain activity and provides EEG data that can help improve patient care.

The RNS System is a treatment for adults with drug-resistant focal epilepsy. The NeuroPace website describes the benefits of their platform with these three key benefits...

The RNS System can help patients achieve significant seizure reduction and quality of life improvements.

Data from the RNS System provides unprecedented visibility into seizure trends and triggers that can help physicians optimize patient treatment plans.

The RNS System responds to a patient’s unique seizure fingerprint -- so patients get the treatment they need when they need it.

A Longer Path to EPS Growth

The reason that NPCE is in the cellar of the Zacks Rank is due to recent disappointments in their quarterly earnings reports.

After their most recent report, the three Wall Street analysts providing earnings model coverage revised their consensus EPS projection down 52% for this year from a loss of $1.29 to a loss of $1.96.

And the Zacks EPS consensus for 2023 was dropped 51% from a loss of $1.04 to a loss of $1.57.

The good news is that for now, the 2023 consensus projection for $56.7 million in revenue, representing 22.8% growth, is still intact. This means the stock is trading under four times forward sales estimates.

NeuroPace is an exciting company with what appears to be an innovative solution to treating epilepsy. As soon as earnings estimates stop going down and stabilize, it could be a welcome addition to a portfolio seeking small-cap medical device growth.

The Zacks Rank will let you know.

Breakout Biotech Stocks with Triple-Digit Profit Potential

The biotech sector is projected to surge beyond $2.4 trillion by 2028 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.

Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Recommendations from previous editions of this report have produced gains of +205%, +258%, and +477%. The stocks in this report could perform even better.